股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 本月底法定/註冊股本總額： HKD 100,000,000 FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 致：香港交易及結算所有限公司 公司名稱: 紫元元控股集團有限公司 呈交日期: 2025年11月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08223 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | HKD | | 0.1 HKD | | 100,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 ...

Financial Proceeds - The net proceeds from the subscription of new shares amounted to approximately HKD 43.5 million, fully allocated to the operational funding of the medical device and consumables trading business [3]. - All proceeds have been utilized within the fiscal year without significant changes or delays compared to the originally disclosed intentions [3].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 紫元元控股集團有限公司 呈交日期: 2025年10月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08223 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | HKD | | 0.1 | HKD | | 100,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 1,000,000,000 | HKD | | 0.1 | HKD | | 100,000,000 | 本月底法定/註冊 ...

紫元元控股集團有限公司 (Incorporated in the Cayman Islands with limited liability) (Stock Code: 8223) （於開曼群島註冊成立的有限公司） （股份代號：8223） NOTIFICATION LETTER 通知信函 Dear Non-registered Shareholder(s) (Note 1) , 30 September 2025 Ziyuanyuan Holdings Group Limited (the "Company") – Notification of publication of Interim Report 2025 (the "Current Corporate Communication") Ziyuanyuan Holdings Group Limited Yours faithfully, Ziyuanyuan Holdings Group Limited Notes: 各位非登記股東 （附註1） ： 紫元元控股集團有限公司（「本公司」） －刊發2025中期報告（「本次公司通訊」） The Englis ...

(Stock Code: 8223) （於開曼群島註冊成立的有限公司） Ziyuanyuan Holdings Group Limited 紫元元控股集團有限公司 (Incorporated in the Cayman Islands with limited liability) （股份代號：8223） NOTIFICATION LETTER 通知信函 Dear Registered Shareholders. 30 September 2025 Ziyuanyuan Holdings Group Limited (the "Company") – Notice of publication of Interim Report 2025 (the "Current Corporate Communication") The English and Chinese versions of the Company's Current Corporate Communications are now available on the Company's website at www.ziyygroup.com a ...

Financial Performance - The company reported a significant increase in revenue, achieving a total of $XX million, representing a YY% growth compared to the previous period[2]. - Total revenue for the six months ended June 30, 2025, was RMB 203,609,000, an increase of 8.1% from RMB 187,326,000 in the same period of 2024[18]. - Income from trading of medical equipment and consumables rose to RMB 195,437,000, up 21.8% from RMB 160,410,000 year-over-year[18]. - The company reported a profit and total comprehensive income of RMB 6,675,000 for the period, up from RMB 6,183,000 in 2024, representing an increase of 8.0%[18]. - For the six months ended June 30, 2025, the profit attributable to owners of the Company was RMB 6,755,000, an increase from RMB 6,042,000 in the same period of 2024, representing a growth of approximately 11.8%[63]. - The company recorded a profit before income tax of RMB 8,724,000 for the six months ended June 30, 2025[41]. - The total revenue for the reportable segments in the previous year (2024) was RMB 187,326,000, indicating growth in 2025[44]. User Engagement and Market Expansion - User data showed an increase in active users, reaching ZZ million, which is an increase of AA% year-over-year[2]. - The company is expanding its market presence in the Asia-Pacific region, targeting a growth rate of DD% in this segment over the next year[2]. - The company provided a positive outlook for the next quarter, projecting revenue growth of BB% and an increase in user engagement metrics[2]. Product Development and Innovation - New product launches are expected to contribute an additional $CC million in revenue, with a focus on innovative features and user experience[2]. - Ongoing research and development efforts have led to the introduction of new technologies, which are anticipated to enhance operational efficiency by EE%[2]. Cost Management and Profitability - Cost management strategies have been implemented, resulting in a reduction of operational expenses by FF%, improving overall profitability[2]. - Staff costs decreased from RMB 13.7 million for the Prior Period to approximately RMB 7.3 million for the Period[139]. - Other operating expenses decreased from approximately RMB 17.8 million for the Prior Period to approximately RMB 13.7 million for the Period[145]. Financial Position and Assets - Net current assets increased to RMB 288,208,000, compared to RMB 237,070,000 at the end of 2024, indicating a growth of 21.6%[20]. - Total equity as of June 30, 2025, was RMB 314,960,000, up from RMB 302,087,000 at the end of 2024, reflecting a growth of 4.9%[21]. - Non-current assets decreased to RMB 138,802,000 from RMB 162,839,000, a decline of 14.8%[20]. Financing Activities - The company issued new shares amounting to RMB 40,000,000 during the period, contributing to its financing activities[34]. - The Company issued Convertible Bonds I with an aggregate principal amount of HK$52,000,000, with a maximum of 34,437,085 ordinary shares potentially issuable upon full conversion[107]. - Convertible Bonds I bear an interest rate of 6% per annum, maturing 18 months from the date of issue, with an initial conversion price of HK$1.51 per share[106]. Sustainability and Corporate Responsibility - Management emphasized the importance of sustainability initiatives, with plans to reduce carbon emissions by HH% over the next five years[2]. Segment Performance - For the six months ended June 30, 2025, the reportable segment revenue totaled RMB 203,609,000, with the finance leasing service contributing RMB 3,813,000, trading business RMB 195,437,000, postpartum care service RMB 4,110,000, and other segment RMB 249,000[41]. - The reportable segment profit for the same period was RMB 19,144,000, with finance leasing service profit at RMB 7,814,000, trading business profit at RMB 12,064,000, and postpartum care service loss at RMB 1,181,000[41]. Cash Flow and Liquidity - Net cash used in operating activities improved to RMB (30,344,000) in 2025 from RMB (111,337,000) in 2024, indicating a reduction in cash outflow by approximately 72.7%[24]. - The company reported a net increase in cash and cash equivalents of RMB 7,030,000 for the six months ended June 30, 2025, compared to a net decrease of RMB (87,953,000) in 2024[24]. - As of June 30, 2025, bank balances and cash were approximately RMB 21.4 million, up from RMB 13.0 million as of December 31, 2024[157]. Shareholder Information - The company aims to enhance shareholder value through a proposed dividend increase of GG% in the upcoming fiscal year[2]. - Directors and chief executives held a total of 300 million shares, representing approximately 69.77% of the shareholding[186].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 紫元元控股集團有限公司 呈交日期: 2025年9月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08223 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | HKD | | 0.1 | HKD | | 100,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 1,000,000,000 | HKD | | 0.1 | HKD | | 100,000,000 | 本月底法定/註冊股 ...

紫元元(08223)发布2025年中期业绩，总收益2.04亿元(人民币，下同)，同比增长8.7%;公司拥有人应占溢 利675.5万元，同比增长11.8%;每股基本盈利1.57分。 ...

智通财经APP讯，紫元元(08223)发布2025年中期业绩，总收益2.04亿元(人民币，下同)，同比增长8.7%; 公司拥有人应占溢利675.5万元，同比增长11.8%;每股基本盈利1.57分。 ...

紫元元控股集團有限公司 Ziyuanyuan Holdings Group Limited （於開曼群島註冊成立的有限公司） （股份代號：8223） 截至二零二五年六月三十日止六個月 中期業績公告 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM乃為較於聯交所上市的其他公司可能帶有更高投資風險的中小型公司而設的市場。有意 投資者應了解投資於該等公司的潛在風險，並應經過審慎周詳考慮後方作出投資決定。 由於GEM上市公司普遍為中小型公司，於GEM買賣的證券可能會較於聯交所主板買賣的證 券承受較大的市場波動風險，同時無法保證於GEM買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本公告的內容概不負責，對其準確性或完整性亦不發 表任何聲明，並明確表示，概不就因本公告全部或任何部份內容而產生或因倚賴該等內容而 引致的任何損失承擔任何責任。 本公告乃遵照聯交所GEM證券上市規則（「GEM上市規則」）的規定而提供有關紫元元控股集 團有限公司（「本公司」）的資料，本公司之董事（「董事」）願就本公告共同及個別地承擔全部責 任。董事在作出一切合理查詢後，確認就彼等所知及所信，本公告所載資料在各重要方面均 ...